Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VEGFR-3-IN-1 is a novel potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.VEGFR-3-IN-1 possesses antitumor activity, inactivates the VEGFR3 signaling pathway, and inhibits the proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231 and MDA-MB-436 cells. MB-436 cells and inhibited the proliferation and migration of human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231 and MDA-MB-436 cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 163.00 | |
5 mg | In stock | $ 413.00 | |
10 mg | In stock | $ 617.00 | |
25 mg | In stock | $ 983.00 | |
50 mg | In stock | $ 1,330.00 | |
100 mg | In stock | $ 1,790.00 | |
500 mg | In stock | $ 3,580.00 |
Description | VEGFR-3-IN-1 is a novel potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.VEGFR-3-IN-1 possesses antitumor activity, inactivates the VEGFR3 signaling pathway, and inhibits the proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231 and MDA-MB-436 cells. MB-436 cells and inhibited the proliferation and migration of human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231 and MDA-MB-436 cells. |
Targets&IC50 | VEGFR3:110.4 nM |
Molecular Weight | 616.1 |
Formula | C29H29ClF3N7OS |
CAS No. | 2756668-73-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (8.12 mM), when pH is adjusted to 6 with HCl. Sonication and heating are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VEGFR-3-IN-1 2756668-73-0 Angiogenesis Tyrosine Kinase/Adaptors VEGFR inhibitor inhibit